273 related articles for article (PubMed ID: 38172449)
21. Antibody Drug Conjugates in the Treatment of Epithelial Ovarian Cancer.
Richardson DL; Seward SM; Moore KN
Hematol Oncol Clin North Am; 2018 Dec; 32(6):1057-1071. PubMed ID: 30390760
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic strategies targeting folate receptor α for ovarian cancer.
Mai J; Wu L; Yang L; Sun T; Liu X; Yin R; Jiang Y; Li J; Li Q
Front Immunol; 2023; 14():1254532. PubMed ID: 37711615
[TBL] [Abstract][Full Text] [Related]
23. Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer.
Gonzalez-Ochoa E; Veneziani AC; Oza AM
Clin Med Insights Oncol; 2023; 17():11795549231187264. PubMed ID: 37528890
[TBL] [Abstract][Full Text] [Related]
24. Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments.
Nagayama A; Ellisen LW; Chabner B; Bardia A
Target Oncol; 2017 Dec; 12(6):719-739. PubMed ID: 29116596
[TBL] [Abstract][Full Text] [Related]
25. Tisotumab vedotin for the treatment of cervical carcinoma.
Song X; Li R; Wang H; Song P; Guo W; Chen ZS
Drugs Today (Barc); 2022 May; 58(5):213-222. PubMed ID: 35535813
[TBL] [Abstract][Full Text] [Related]
26. Mirvetuximab soravtansine in ovarian cancer therapy: expert opinion on pharmacological considerations.
Nwabufo CK
Cancer Chemother Pharmacol; 2024 Feb; 93(2):89-105. PubMed ID: 37594572
[TBL] [Abstract][Full Text] [Related]
27. A review of recent advances on single use of antibody-drug conjugates or combination with tumor immunology therapy for gynecologic cancer.
Wang AJ; Gao Y; Shi YY; Dai MY; Cai HB
Front Pharmacol; 2022; 13():1093666. PubMed ID: 36618922
[TBL] [Abstract][Full Text] [Related]
28. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer.
Moore KN; O'Malley DM; Vergote I; Martin LP; Gonzalez-Martin A; Malek K; Birrer MJ
Gynecol Oncol; 2018 Oct; 151(1):46-52. PubMed ID: 30093227
[TBL] [Abstract][Full Text] [Related]
29. Antibody-drug conjugates for ovarian cancer: current clinical development.
Stewart D; Cristea M
Curr Opin Obstet Gynecol; 2019 Feb; 31(1):18-23. PubMed ID: 30531606
[TBL] [Abstract][Full Text] [Related]
30. Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer.
Najjar MK; Manore SG; Regua AT; Lo HW
Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36360302
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of mirvetuximab soravtansine in recurrent ovarian cancer with FRa positive expression: A systematic review and meta-analysis.
Wang Y; Liu L; Jin X; Yu Y
Crit Rev Oncol Hematol; 2024 Feb; 194():104230. PubMed ID: 38122916
[TBL] [Abstract][Full Text] [Related]
32. Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models.
Ponte JF; Ab O; Lanieri L; Lee J; Coccia J; Bartle LM; Themeles M; Zhou Y; Pinkas J; Ruiz-Soto R
Neoplasia; 2016 Dec; 18(12):775-784. PubMed ID: 27889646
[TBL] [Abstract][Full Text] [Related]
33. Implementation of antibody-drug conjugates in HER2-positive solid cancers: Recent advances and future directions.
Yu J; Li M; Liu X; Wu S; Li R; Jiang Y; Zheng J; Li Z; Xin K; Xu Z; Li S; Chen X
Biomed Pharmacother; 2024 May; 174():116522. PubMed ID: 38565055
[TBL] [Abstract][Full Text] [Related]
34. Revisiting antibody-drug conjugates and their predictive biomarkers in platinum-resistant ovarian cancer.
El Bairi K; Al Jarroudi O; Afqir S
Semin Cancer Biol; 2021 Dec; 77():42-55. PubMed ID: 33812984
[TBL] [Abstract][Full Text] [Related]
35. Clinical perspective: Antibody-drug conjugates for the treatment of HER2-positive breast cancer.
Najminejad Z; Dehghani F; Mirzaei Y; Mer AH; Saghi SA; Abdolvahab MH; Bagheri N; Meyfour A; Jafari A; Jahandideh S; Gharibi T; Amirkhani Z; Delam H; Mashatan N; Shahsavarani H; Abdollahpour-Alitappeh M
Mol Ther; 2023 Jul; 31(7):1874-1903. PubMed ID: 36950736
[TBL] [Abstract][Full Text] [Related]
36. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.
Moore KN; Martin LP; O'Malley DM; Matulonis UA; Konner JA; Perez RP; Bauer TM; Ruiz-Soto R; Birrer MJ
J Clin Oncol; 2017 Apr; 35(10):1112-1118. PubMed ID: 28029313
[TBL] [Abstract][Full Text] [Related]
37. Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.
Lambert JM; Morris CQ
Adv Ther; 2017 May; 34(5):1015-1035. PubMed ID: 28361465
[TBL] [Abstract][Full Text] [Related]
38. A review of the novel tissue factor antibody-drug conjugate: Tisotumab vedotin.
Luu K; Chu A; Chang B
J Oncol Pharm Pract; 2023 Mar; 29(2):441-449. PubMed ID: 36415085
[TBL] [Abstract][Full Text] [Related]
39. Progress in Gynecologic Cancers with Antibody Drug Conjugates.
O'Malley DM; Calo CA
Curr Oncol Rep; 2021 Jun; 23(8):89. PubMed ID: 34125311
[TBL] [Abstract][Full Text] [Related]
40. Antibody-Drug Conjugates for Breast Cancer.
Marmé F
Oncol Res Treat; 2022; 45(1-2):26-36. PubMed ID: 34915488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
